GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Beta

Equillium (FRA:0FY) Beta : -0.23 (As of Apr. 30, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Equillium Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-30), Equillium's Beta is -0.23.


Equillium Beta Historical Data

The historical data trend for Equillium's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Beta Chart

Equillium Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial - - -0.84 -0.61 0.08

Equillium Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -1.69 -1.75 -1.09 0.08

Competitive Comparison of Equillium's Beta

For the Biotechnology subindustry, Equillium's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Equillium's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Beta distribution charts can be found below:

* The bar in red indicates where Equillium's Beta falls into.



Equillium Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Equillium  (FRA:0FY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Equillium Beta Related Terms

Thank you for viewing the detailed overview of Equillium's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Equillium (FRA:0FY) Business Description

Traded in Other Exchanges
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (FRA:0FY) Headlines

No Headlines